Immunocore Holdings plc - ADR
IMCR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.51B
Close$
$-21.06
170.9% downside
Current Fair Value
170.9% downsideOvervalued by 170.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.51 Billion |
|---|---|
| Enterprise Value | $1.46 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.74 |
| Outstanding Shares | 50,973,830 |
Return
| Return on Equity | -2.22% |
|---|---|
| Return on Assets | -0.83% |
| Return on Invested Capital | -0.78% |
Valuation & Multiples
| P/E Ratio | -164.78 |
|---|---|
| PEG | 178.81 |
| Price to Sales | 4.24 |
| Price to Book Ratio | 3.71 |
| Enterprise Value to Revenue | 3.62 |
| Enterprise Value to EBIT | -210.46 |
| Enterprise Value to Net Income | -157 |
| Total Debt to Enterprise | 0.3 |
| Debt to Equity | 1.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$148.84 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$152.86 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.0387▼ 560.96% |
|---|---|
| Total Calls | 173,100▼ 8.99% |
| Total Puts | 526,000▼ 68.02% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 102.22%▼ 1.01% |
|---|---|
| Total Invested | $1.65B▲ 4.69% |
| Investors Holding | 145▼ 8.00% |
ESG Score
No data
About Immunocore Holdings plc
2,020 employeesImmunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of disea...